4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 9,530,000 shares, a decrease of 7.8% from the July 15th total of 10,340,000 shares. Based on an average daily trading volume, of 874,700 shares, the short-interest ratio is currently 10.9 days.
Insider Activity
In related news, CEO David Kirn sold 12,930 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $23.10, for a total value of $298,683.00. Following the sale, the chief executive officer now directly owns 1,059,153 shares in the company, valued at $24,466,434.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other 4D Molecular Therapeutics news, insider Scott Bizily sold 1,750 shares of the stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $27.11, for a total transaction of $47,442.50. Following the completion of the sale, the insider now directly owns 6,781 shares in the company, valued at approximately $183,832.91. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO David Kirn sold 12,930 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $23.10, for a total value of $298,683.00. Following the completion of the transaction, the chief executive officer now directly owns 1,059,153 shares of the company’s stock, valued at $24,466,434.30. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,847 shares of company stock valued at $777,401. Company insiders own 7.30% of the company’s stock.
Hedge Funds Weigh In On 4D Molecular Therapeutics
Hedge funds have recently bought and sold shares of the company. Bfsg LLC bought a new position in shares of 4D Molecular Therapeutics during the fourth quarter valued at about $30,000. Allspring Global Investments Holdings LLC lifted its position in shares of 4D Molecular Therapeutics by 702.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after buying an additional 3,026 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of 4D Molecular Therapeutics by 23.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 5,872 shares of the company’s stock worth $119,000 after buying an additional 1,110 shares during the last quarter. Quest Partners LLC grew its holdings in shares of 4D Molecular Therapeutics by 17,409.1% in the second quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after acquiring an additional 5,745 shares in the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $239,000. 99.27% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on 4D Molecular Therapeutics
4D Molecular Therapeutics Stock Performance
Shares of NASDAQ FDMT opened at $14.31 on Monday. The stock has a market cap of $739.87 million, a price-to-earnings ratio of -5.86 and a beta of 2.83. 4D Molecular Therapeutics has a fifty-two week low of $9.44 and a fifty-two week high of $36.25. The firm’s 50-day simple moving average is $19.82 and its 200 day simple moving average is $24.66.
4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.09. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $1.90 million. On average, sell-side analysts predict that 4D Molecular Therapeutics will post -2.98 EPS for the current year.
4D Molecular Therapeutics Company Profile
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
See Also
- Five stocks we like better than 4D Molecular Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- This Small Cap Wealth Management Stock Could Provide Big Returns
- What Makes a Stock a Good Dividend Stock?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Investing in Commodities: What Are They? How to Invest in Them
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for 4D Molecular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4D Molecular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.